Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Trevor F. Cox et al.|The Lancet Oncology|2014Cited by 374
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancerTarek M. Abdel-Fatah, Srinivasan Madhusudan|Molecular Oncology|2014Cited by 149
Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancerTarek M.A. Abdel-Fatah, Srinivasan Madhusudan|Molecular Oncology|2014Cited by 84
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Daniel H. Palmer et al.|The Lancet Oncology|2017Cited by 73